US 12,269,889 B2
Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels
Haruka Okamoto, New York, NY (US); Mark Sleeman, Richmond (AU); and Joyce Harp, Montclair, NJ (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Oct. 11, 2022, as Appl. No. 18/045,592.
Application 15/415,672 is a division of application No. 14/821,652, filed on Aug. 7, 2015, granted, now 9,587,029, issued on Mar. 7, 2017.
Application 14/821,652 is a division of application No. 14/014,517, filed on Aug. 30, 2013, granted, now 9,127,068, issued on Sep. 8, 2015.
Application 18/045,592 is a continuation of application No. 16/837,930, filed on Apr. 1, 2020, granted, now 11,498,970.
Application 16/837,930 is a continuation of application No. 16/256,190, filed on Jan. 24, 2019, granted, now 10,640,566, issued on May 5, 2020.
Application 16/256,190 is a continuation of application No. 15/415,672, filed on Jan. 25, 2017, granted, now 10,233,250, issued on Mar. 19, 2019.
Application 14/014,517 is a continuation of application No. 13/301,944, filed on Nov. 22, 2011, granted, now 8,545,847, issued on Oct. 1, 2013.
Claims priority of provisional application 61/551,032, filed on Oct. 25, 2011.
Claims priority of provisional application 61/481,958, filed on May 3, 2011.
Claims priority of provisional application 61/416,409, filed on Nov. 23, 2010.
Prior Publication US 2023/0192874 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/40 (2006.01); C07K 16/46 (2006.01); C12N 15/113 (2010.01); C12N 15/64 (2006.01); C12N 15/70 (2006.01)
CPC C07K 16/2869 (2013.01) [A61K 39/39541 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/40 (2013.01); C07K 16/468 (2013.01); C12N 15/1137 (2013.01); C12N 15/64 (2013.01); C12N 15/70 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2320/31 (2013.01)] 20 Claims
 
1. An isolated human antibody or antigen-binding fragment thereof that specifically binds human glucagon receptor (hGCGR), comprising:
(a) a heavy chain complementarity determining region 1 (HCDR1) amino acid sequence as set forth in SEQ ID NO: 36 with no more than one amino acid substitution;
(b) an HCDR2 amino acid sequence as set forth in SEQ ID NO: 38 with no more than one amino acid substitution;
(c) an HCDR3 amino acid sequence as set forth in SEQ ID NO: 40 with no more than one amino acid substitution;
(d) an LCDR1 amino acid sequence as set forth in SEQ ID NO: 44 with no more than one amino acid substitution;
(e) an LCDR2 amino acid sequence as set forth in SEQ ID NO: 46 with no more than one amino acid substitution; and
(f) an LCDR3 amino acid sequence as set forth in SEQ ID NO: 48 with no more than one amino acid substitution.